ANDA 91509, held by Sun Pharmaceutical Industries. Lansoprazole.
As of Nov 21, 2026, ANDA 91509 (Lansoprazole), held by Sun Pharmaceutical Industries, was first approved by FDA on Sep 13, 2013, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 13, 2013 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lansoprazole30MG · capsule, delayed rel pellets;oral | Lansoprazole | Discontinued |
| Sep 2, 2022 | Supplement 22Labeling · Standard review | Approved | None posted |
| Oct 20, 2020 | Supplement 8Labeling · Standard review | Approved | None posted |
| Oct 20, 2020 | Supplement 10Labeling · Standard review | Approved | None posted |
| Oct 20, 2020 | Supplement 11Labeling · Standard review | Approved | None posted |
| Oct 20, 2020 | Supplement 19Labeling · Standard review | Approved | None posted |
| Apr 23, 2015 | Supplement 7Manufacturing | Approved | None posted |
| Mar 2, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Sep 13, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters